Axlovir^TM Combipack

Indication:
Emergency use authorization:
Treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progression to severe COVID-19, including hospitalization or death.

Dosage & Administration:
Axlovir^TM Combipack is administered as three tablets (two tablets of Nirmatrelvir and one tablet of Ritonavir) taken together orally twice daily for five days, for a total of 30 tablets.

Preparation:
Each Combipack contains 3 tablets (02 Nirmatrelvir 150 mg Tablet & 01 Ritonavir 100 mg Tablet) in Alu-Alu blister pack.